Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
150 INR | +1.28% | +1.32% | +8.03% |
May. 14 | Jefferies Adjusts Piramal Pharma’s Price Target to INR180 From INR170, Keeps at Buy | MT |
May. 13 | Transcript : Piramal Pharma Limited, Q4 2024 Earnings Call, May 13, 2024 |
Sales 2024 | 81.71B 979M | Sales 2025 * | 91.69B 1.1B | Capitalization | 199B 2.38B |
---|---|---|---|---|---|
Net income 2024 | 178M 2.13M | Net income 2025 * | 2.23B 26.74M | EV / Sales 2024 | 2.09 x |
Net Debt 2024 * | 33.7B 404M | Net Debt 2025 * | 36.8B 441M | EV / Sales 2025 * | 2.57 x |
P/E ratio 2024 |
921
x | P/E ratio 2025 * |
88
x | Employees | 6,295 |
Yield 2024 * |
0.13% | Yield 2025 * |
0.2% | Free-Float | 26.82% |
Latest transcript on Piramal Pharma Limited
1 day | +1.28% | ||
1 week | +1.32% | ||
Current month | +1.32% | ||
1 month | -2.47% | ||
3 months | +18.20% | ||
6 months | +18.34% | ||
Current year | +8.03% |
Managers | Title | Age | Since |
---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 46 | 20-03-03 |
Vivek Valsaraj
PSD | President | 51 | 20-06-09 |
Vinay Agrawal
COO | Chief Operating Officer | 60 | 20-04-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 43 | 21-01-03 | |
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | - |
Director/Board Member | 76 | 21-02-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 7 M€ | +5.53% | - | |
0.00% | 114 M€ | +4.36% | - | |
0.00% | 32 M€ | +4.30% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 150 | +1.28% | 4,155,462 |
24-06-06 | 148.1 | +1.51% | 2,761,991 |
24-06-05 | 145.9 | +0.76% | 2,360,504 |
24-06-04 | 144.8 | -3.21% | 8,914,511 |
24-06-03 | 149.6 | +1.05% | 5,128,758 |
Delayed Quote NSE India S.E., June 07, 2024 at 07:58 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.03% | 2.38B | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- PPLPHARMA Stock